Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.
A number of other research firms also recently weighed in on SPTX. Wolfe Research began coverage on Seaport Therapeutics in a research note on Tuesday, July 7th. They issued a “hold” rating on the stock. Stifel Nicolaus started coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They set a “buy” rating and a $30.00 target price for the company. Leerink Partners assumed coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 price objective on the stock. Seaport Research Partners set a $50.00 price objective on shares of Seaport Therapeutics in a research note on Wednesday. Finally, Wall Street Zen upgraded Seaport Therapeutics to a “hold” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.40.
Get Our Latest Research Report on SPTX
Seaport Therapeutics Stock Up 0.0%
Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last posted its quarterly earnings data on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.64) by $0.30.
Insider Activity at Seaport Therapeutics
In related news, Director Robert J. Hombach purchased 13,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the acquisition, the director directly owned 13,000 shares in the company, valued at $235,820. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Arch Venture Partners Xii, Llc bought 1,100,000 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the completion of the purchase, the insider directly owned 6,294,951 shares of the company’s stock, valued at approximately $113,309,118. This trade represents a 21.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Featured Articles
- Five stocks we like better than Seaport Therapeutics
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
